164 related articles for article (PubMed ID: 25961696)
1. Prognostic factors in paediatric anaplastic large cell lymphoma: role of ALK.
Damm-Welk C; Pillon M; Woessmann W; Mussolin L
Front Biosci (Schol Ed); 2015 Jun; 7(2):205-16. PubMed ID: 25961696
[TBL] [Abstract][Full Text] [Related]
2. Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK-positive anaplastic large-cell lymphoma.
Damm-Welk C; Mussolin L; Zimmermann M; Pillon M; Klapper W; Oschlies I; d'Amore ES; Reiter A; Woessmann W; Rosolen A
Blood; 2014 Jan; 123(3):334-7. PubMed ID: 24297868
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of minimal disseminated disease and immune response to NPM-ALK in Japanese children with ALK-positive anaplastic large cell lymphoma.
Iijima-Yamashita Y; Mori T; Nakazawa A; Fukano R; Takimoto T; Tsurusawa M; Kobayashi R; Horibe K
Int J Hematol; 2018 Feb; 107(2):244-250. PubMed ID: 29030834
[TBL] [Abstract][Full Text] [Related]
4. Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis.
Mussolin L; Damm-Welk C; Pillon M; Zimmermann M; Franceschetto G; Pulford K; Reiter A; Rosolen A; Woessmann W
Leukemia; 2013 Feb; 27(2):416-22. PubMed ID: 22907048
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and adolescents.
Rigaud C; Knörr F; Brugières L; Woessmann W
Best Pract Res Clin Haematol; 2023 Mar; 36(1):101444. PubMed ID: 36907641
[TBL] [Abstract][Full Text] [Related]
6. Should treatment of ALK-positive anaplastic large cell lymphoma be stratified according to minimal residual disease?
Rigaud C; Abbas R; Grand D; Minard-Colin V; Aladjidi N; Buchbinder N; Garnier N; Plat G; Couec ML; Duplan M; Lambilliotte A; Schmitt C; Leblanc T; Lamant L; Brugières L
Pediatr Blood Cancer; 2021 Jun; 68(6):e28982. PubMed ID: 33687135
[TBL] [Abstract][Full Text] [Related]
7. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease.
Eyre TA; Khan D; Hall GW; Collins GP
Eur J Haematol; 2014 Dec; 93(6):455-68. PubMed ID: 24766435
[TBL] [Abstract][Full Text] [Related]
8. Story of survival in anaplastic large cell lymphoma - sometimes more than the anaplastic lymphoma kinase status: An evaluation of pathologic prognostic factors in 102 cases.
Agrawal K; Shet T; Sridhar E; Dhende S; Sengar M; Arora B; Laskar S; Gujral S; Menon H; Banavali S
Indian J Pathol Microbiol; 2017; 60(4):533-540. PubMed ID: 29323068
[TBL] [Abstract][Full Text] [Related]
9. Quantification of minimal disseminated disease by quantitative polymerase chain reaction and digital polymerase chain reaction for
Damm-Welk C; Kutscher N; Zimmermann M; Attarbaschi A; Schieferstein J; Knörr F; Oschlies I; Klapper W; Woessmann W
Haematologica; 2020 Aug; 105(8):2141-2149. PubMed ID: 31649129
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma.
Gao J; Yin M; Zhu Y; Gu L; Zhang Y; Li Q; Jia C; Ma Z
BMC Cancer; 2013 Oct; 13():471. PubMed ID: 24112608
[TBL] [Abstract][Full Text] [Related]
11. Anaplastic large cell lymphoma, ALK-negative.
Ferreri AJ; Govi S; Pileri SA; Savage KJ
Crit Rev Oncol Hematol; 2013 Feb; 85(2):206-15. PubMed ID: 22789917
[TBL] [Abstract][Full Text] [Related]
12. The NADPH oxidase NOX5 protects against apoptosis in ALK-positive anaplastic large-cell lymphoma cell lines.
Carnesecchi S; Rougemont AL; Doroshow JH; Nagy M; Mouche S; Gumy-Pause F; Szanto I
Free Radic Biol Med; 2015 Jul; 84():22-29. PubMed ID: 25797883
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological features and prognostic significance of programmed death ligand 1 in pediatric ALK-positive anaplastic large cell lymphoma: results of the ALCL99 treatment in Japan.
Iwafuchi H; Nakazawa A; Sekimizu M; Mori T; Osumi T; Iijima-Yamashita Y; Ohki K; Kiyokawa N; Fukano R; Saito AM; Horibe K; Kobayashi R;
Hum Pathol; 2021 Oct; 116():112-121. PubMed ID: 34363798
[TBL] [Abstract][Full Text] [Related]
14. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas.
Drexler HG; Gignac SM; von Wasielewski R; Werner M; Dirks WG
Leukemia; 2000 Sep; 14(9):1533-59. PubMed ID: 10994999
[TBL] [Abstract][Full Text] [Related]
15. ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors.
Lovisa F; Cozza G; Cristiani A; Cuzzolin A; Albiero A; Mussolin L; Pillon M; Moro S; Basso G; Rosolen A; Bonvini P
PLoS One; 2015; 10(4):e0121378. PubMed ID: 25874976
[TBL] [Abstract][Full Text] [Related]
16. [Prognostic significance of the NPM-ALK fusion gene in bone marrow and peripheral blood for patients with anaplastic large cell lymphoma].
Yang J; Zhao XX; Jin L; Duan YL; Huang S; Zhang M; Zhang R; Zhou CJ; Zhang YH
Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):700-3. PubMed ID: 23978023
[TBL] [Abstract][Full Text] [Related]
17. Clinical and laboratory characteristics of systemic anaplastic large cell lymphoma in Chinese patients.
Wang YF; Yang YL; Gao ZF; Zhou CJ; Gregg X; Shi YF; Wang J; Yang XF; Ke XY
J Hematol Oncol; 2012 Jul; 5():38. PubMed ID: 22769020
[TBL] [Abstract][Full Text] [Related]
18. Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk.
Ait-Tahar K; Damm-Welk C; Burkhardt B; Zimmermann M; Klapper W; Reiter A; Pulford K; Woessmann W
Blood; 2010 Apr; 115(16):3314-9. PubMed ID: 20185586
[TBL] [Abstract][Full Text] [Related]
19. Quantification of Minimal Disease by Digital PCR in ALK-Positive Anaplastic Large Cell Lymphoma: A Step towards Risk Stratification in International Trials?
Damm-Welk C; Lovisa F; Contarini G; Lüdersen J; Carraro E; Knörr F; Förster J; Zimmermann M; Sala A; Vinti L; Tondo A; Pillon M; Woessmann W; Mussolin L
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406475
[TBL] [Abstract][Full Text] [Related]
20. ALK expression plays different roles in anaplastic large-cell lymphomas and outcome of crizotinib use in relapsed/refractory ALK+ patients in a Chinese population.
Huang L; Zhang F; Zeng J; Guo H; Liu S; Wei X; Chen F; Jiang X; Liang Z; Liu Y; Li W
Ann Hematol; 2018 Jan; 97(1):149-159. PubMed ID: 29150811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
